241 related articles for article (PubMed ID: 29967228)
1. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
2. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
3. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
[No Abstract] [Full Text] [Related]
4. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
[TBL] [Abstract][Full Text] [Related]
5. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
[TBL] [Abstract][Full Text] [Related]
6. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
Sano M; Goto S
Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
[No Abstract] [Full Text] [Related]
7. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
Lahnwong C; Chattipakorn SC; Chattipakorn N
Cardiovasc Diabetol; 2018 Jul; 17(1):101. PubMed ID: 29991346
[TBL] [Abstract][Full Text] [Related]
8. Research digest: new horizons in heart failure therapy.
Sattar N; Preiss D
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):832. PubMed ID: 31621593
[No Abstract] [Full Text] [Related]
9. New anti-diabetic agents: major advances with unanswered questions.
Sabouret P; Bocchino PP; Biondi-Zoccai G
Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
[TBL] [Abstract][Full Text] [Related]
10. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM; Inzucchi SE; Voors AA
Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
[No Abstract] [Full Text] [Related]
11. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
12. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Liu H; Sridhar VS; Boulet J; Dharia A; Khan A; Lawler PR; Cherney DZI
Metabolism; 2022 Jan; 126():154918. PubMed ID: 34699838
[TBL] [Abstract][Full Text] [Related]
13. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
Bailey CJ
Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
[No Abstract] [Full Text] [Related]
14. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
15. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
16. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Greene SJ; Butler J
Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
[No Abstract] [Full Text] [Related]
17. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
18. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
19. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
20. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
Reid T
J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]